These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35841237)

  • 21. Accelerating Alzheimer's disease drug innovations from the research pipeline to patients.
    Goldman DP; Fillit H; Neumann P
    Alzheimers Dement; 2018 Jun; 14(6):833-836. PubMed ID: 29680407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Siemers E
    J Prev Alzheimers Dis; 2019; 6(3):180-181. PubMed ID: 31062831
    [No Abstract]   [Full Text] [Related]  

  • 23. Considerations for future tau-targeted therapeutics: can they deliver?
    Noble W; Jimenez-Sanchez M; Perez-Nievas BG; Hanger DP
    Expert Opin Drug Discov; 2020 Mar; 15(3):265-267. PubMed ID: 31661994
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial: Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2, 2022.
    Weiner MW
    J Prev Alzheimers Dis; 2022; 9(S1):S3-S4. PubMed ID: 36471005
    [No Abstract]   [Full Text] [Related]  

  • 26. Dominantly inherited Alzheimer's disease: a compass for drug development.
    Rabinovici GD
    Nat Med; 2021 Jul; 27(7):1148-1150. PubMed ID: 34226734
    [No Abstract]   [Full Text] [Related]  

  • 27. Alzheimer's Disease: Dawn of a New Era?
    Amirrad F; Bousoik E; Shamloo K; Al-Shiyab H; Nguyen VV; Montazeri Aliabadi H
    J Pharm Pharm Sci; 2017; 20(0):184-225. PubMed ID: 28719360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Be open about drug failures to speed up research.
    Alteri E; Guizzaro L
    Nature; 2018 Nov; 563(7731):317-319. PubMed ID: 30425369
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial: Failure After Failure. What Next in AD Drug Development?
    Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):150. PubMed ID: 31062821
    [No Abstract]   [Full Text] [Related]  

  • 30. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.
    Wessels AM; Edgar CJ; Nathan PJ; Siemers ER; Maruff P; Harrison J
    Drug Discov Today; 2021 May; 26(5):1330-1336. PubMed ID: 33486115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets.
    Sierksma A; Escott-Price V; De Strooper B
    Science; 2020 Oct; 370(6512):61-66. PubMed ID: 33004512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alzheimer's disease: A need for personalized therapeutic approaches.
    Frenkel D
    Drug Dev Res; 2020 Apr; 81(2):141-143. PubMed ID: 32125005
    [No Abstract]   [Full Text] [Related]  

  • 33. Mitochondrial dysfunction: A potential target for Alzheimer's disease intervention and treatment.
    Ke J; Tian Q; Xu Q; Fu Z; Fu Q
    Drug Discov Today; 2021 Aug; 26(8):1991-2002. PubMed ID: 33962036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business.
    Aisen PS; Raman R
    J Prev Alzheimers Dis; 2020; 7(3):195-196. PubMed ID: 32463073
    [No Abstract]   [Full Text] [Related]  

  • 35. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.
    Vellas B; Bain LJ; Touchon J; Aisen PS
    J Prev Alzheimers Dis; 2019; 6(3):198-203. PubMed ID: 31062835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
    Schneider LS; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M
    J Intern Med; 2014 Mar; 275(3):251-83. PubMed ID: 24605808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why have transgenic rodent models failed to successfully mimic Alzheimer's disease. How can we develop effective drugs without them?
    Franco R; Martínez-Pinilla E; Navarro G
    Expert Opin Drug Discov; 2019 Apr; 14(4):327-330. PubMed ID: 30775940
    [No Abstract]   [Full Text] [Related]  

  • 38. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
    Knopman DS; Haeberlein SB; Carrillo MC; Hendrix JA; Kerchner G; Margolin R; Maruff P; Miller DS; Tong G; Tome MB; Murray ME; Nelson PT; Sano M; Mattsson N; Sultzer DL; Montine TJ; Jack CR; Kolb H; Petersen RC; Vemuri P; Canniere MZ; Schneider JA; Resnick SM; Romano G; van Harten AC; Wolk DA; Bain LJ; Siemers E
    Alzheimers Dement; 2018 Apr; 14(4):563-575. PubMed ID: 29653607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.
    Maciejewska K; Czarnecka K; Szymański P
    Pharmacol Rep; 2021 Dec; 73(6):1565-1581. PubMed ID: 34121170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.